| Efficacy of an Infrared Visualization Technique for the Identification of the Peripheral Venous Access Site in Patients With Cystic Fibrosis Aged 12 Years and Older (NCT04226118) | Hospices Civils de Lyon | 2021-01-19 |
| Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals (NCT03226795) | Hospices Civils de Lyon | 2021-01-18 |
| The Impact of Patch Rx Technologies on Adherence to Vitamin and Trikafta Therapies in Patients With Cystic Fibrosis (NCT04684823) | The University of Texas Health Science Center at San Antonio | 2021-01-15 |
| A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) (NCT04599465) | Vertex Pharmaceuticals Incorporated | 2021-01-15 |
| Feasibility of a Goal-based Agenda Setting Intervention (NCT04696484) | Dartmouth-Hitchcock Medical Center | 2021-01-14 |
| SELF-BREATHE RCT for Chronic Breathlessness (NCT04574050) | King's College Hospital NHS Trust | 2021-01-11 |
| A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes (NCT04545515) | Vertex Pharmaceuticals Incorporated | 2021-01-11 |
| Physical Activity, Exercise Capacity and Coronavirus Phobia of Adult Cystic Fibrosis Patients During COVID-19 Pandemic (NCT04673331) | Hacettepe University | 2021-01-05 |
| Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients (NCT04735679) | University Hospital, Montpellier | 2021-01-01 |
| Effects of a Telerehabilitation Approach in Children With Cystic Fibrosis (NCT04683809) | Marmara University | 2021-01-01 |
| Medication Adherence and Non-adherence in Adults With Rare Disease (NCT04541875) | Xperiome | 2021-01-01 |
| Effect of the CFTR-modulating Triple Therapy Elexacaftor - Tezacaftor - Ivacaftor (NCT05576324) | University of Erlangen-Nürnberg Medical School | 2020-12-30 |
| The Effects of Telerehabilitation on Muscle Function, Physical Activity and Sleep in Cystic Fibrosis During Pandemic (NCT04742049) | Hacettepe University | 2020-12-28 |
| Qualitative Understanding of Experiences With the SIMPLIFY Trial (NCT04320381) | Boston Children's Hospital | 2020-12-23 |
| Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis (NCT04596319) | Armata Pharmaceuticals, Inc. | 2020-12-22 |
| Evaluation of Lung T1-MRI in Pediatric Cystic Fibrosis Patients (NCT04994301) | University Hospitals Cleveland Medical Center | 2020-12-15 |
| Prospective Analysis of Urine LAM to Eliminate NTM Sputum Screening (NCT04579211) | Jerry A. Nick, M.D. | 2020-12-10 |
| A Pilot Study to Assess the Effect of Intermittent iNO on the Treatment of NTM Lung Infection in CF and Non-CF Patients (NCT04685720) | Beyond Air Inc. | 2020-12-07 |
| Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis (NCT02547116) | Johns Hopkins University | 2020-12-01 |
| Feasibility of a New Model for Exercise Prescription in Cystic Fibrosis (NCT04075864) | University of Alabama at Birmingham | 2020-12-01 |
| Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis (NCT03058068) | Joshua M Hare | 2020-12-01 |
| Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 Years (NCT04537793) | Vertex Pharmaceuticals Incorporated | 2020-11-19 |
| Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children (NCT04509050) | Sonya Heltshe | 2020-11-18 |
| Exercise in Child Health (NCT05359991) | University of California, Irvine | 2020-11-12 |
| Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders (NCT02748798) | Thunder Bay Regional Health Research Institute | 2020-11-10 |
| Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease (NCT04624490) | Mario Castro, MD, MPH | 2020-11-02 |
| The Effect of Telerehabilitation on Functional Capacity, Oxidative Stress and Respiratory Parameters in Cystic Fibrosis (NCT05147285) | Hacettepe University | 2020-10-22 |
| Gut Imaging for Function & Transit in CF - GIFT-CF 3 (NCT04618185) | Nottingham University Hospitals NHS Trust | 2020-10-21 |
| Proximal Intestinal Obstruction Syndrome (PIOS) in a Patient With Cystic Fibrosis: A New Syndrome (NCT04613063) | Tecnologico de Monterrey | 2020-10-19 |
| Manual Chest Physiotherapy and Active Cycle of Breathing Techniques (ACBT) in Patients of Cystic Fibrosis (NCT05026918) | Riphah International University | 2020-10-13 |
| Microbial Biomarkers of EArly Pseudomonas Aeruginosa Colonization in CHildren With Cystic Fibrosis (NCT03947957) | University Hospital, Brest | 2020-10-02 |
| Polyethylene Glycol and Intestinal Inflammation in Cystic Fibrosis (NCT04458129) | University Hospital, Bordeaux | 2020-09-29 |
| Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) (NCT04602468) | Royal College of Surgeons, Ireland | 2020-09-03 |
| Cystic Fibrosis Remote Monitoring System (NCT04453358) | Koronis Biomedical Technologies | 2020-09-01 |
| Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study (NCT06350461) | Nicole Hamblett | 2020-08-25 |
| Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (NCT06350474) | Nicole Hamblett | 2020-08-25 |
| Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (NCT04378153) | Nicole Hamblett | 2020-08-25 |
| Vitamin K Supplementation to Reduce Deficiencies in Adults With Cystic Fibrosis (NCT04496921) | Institut de Recherches Cliniques de Montreal | 2020-08-10 |
| Pulmonary Vascular Disease in CF (NCT04549077) | Children's Hospital Medical Center, Cincinnati | 2020-07-29 |
| Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF (NCT04553419) | University of British Columbia | 2020-07-27 |
| Study to Evaluate the Safety of CB-280 in Patients With Cystic Fibrosis (NCT04279769) | Calithera Biosciences, Inc | 2020-07-03 |
| Using NPT to Evaluate Providing PPC as ELNEC-PPC WBT for Nurses (NCT04461561) | Altoosi University College | 2020-07-01 |
| Impact of Sinus Surgery on Individuals With Cystic Fibrosis (NCT04469439) | University of California, Los Angeles | 2020-07-01 |
| Prospective Surveillance of Lung Development During Childhood, Adolescence and Adulthood in Healthy and Patients With Cystic Fibrosis (NCT04395820) | Insel Gruppe AG, University Hospital Bern | 2020-07-01 |
| A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes (NCT04353817) | Vertex Pharmaceuticals Incorporated | 2020-06-19 |
| Diet, Physical Activity and Glucose Tolerance in Cystic Fibrosis. Exploratory Study. (NCT04249466) | Hospices Civils de Lyon | 2020-06-05 |
| Patient Outcomes of Clinic Transition From Face to Face Encounter to Telemedicine in Cystic Fibrosis (NCT04402801) | University of Virginia | 2020-06-01 |
| Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic (NCT04463628) | Centre Hospitalier Intercommunal Creteil | 2020-05-15 |
| Evaluation of the ReX-C System, in Patients Receiving CFTR Modulators for the Treatment of Cystic Fibrosis (CF). (NCT04215796) | Dosentrx Ltd. | 2020-05-12 |
| ActivOnline: Physical Activity in Cystic Fibrosis Trial UK (NCT04249999) | University of Exeter | 2020-05-07 |
| A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy (NCT04362761) | Vertex Pharmaceuticals Incorporated | 2020-05-04 |
| Implementation of a Clinical Tool to Improve Waitlist Mortality in Patients With Cystic Fibrosis (NCT04687475) | The Cleveland Clinic | 2020-04-20 |
| Vitamin D and Prebiotics for Intestinal Health in Cystic Fibrosis (NCT04118010) | Emory University | 2020-03-13 |
| Organoid Study R334W (NCT04254705) | Universitaire Ziekenhuizen KU Leuven | 2020-03-01 |
| Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary Exacerbations (NCT04341532) | National Jewish Health | 2020-02-20 |
| Technology-enabled Patient Support System for Self-management of CF (NCT03910881) | University of Alabama at Birmingham | 2020-02-18 |
| Non-pulmonary Contributors of Exercise Intolerance in Patients With Cystic Fibrosis (NCT04166396) | Virginia Commonwealth University | 2020-02-17 |
| Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older (NCT04183790) | Vertex Pharmaceuticals Incorporated | 2020-02-17 |
| Effects of Innovative Aerobic Exercise Training in Cystic Fibrosis (NCT04543929) | University of Kansas Medical Center | 2020-02-11 |
| Tele-Coaching Intervention to Improve Treatment Adherence in Cystic Fibrosis (NCT03921229) | Boston Children's Hospital | 2020-01-13 |
| Hyperpolarized Imaging for New Treatments (NCT04259970) | Children's Hospital Medical Center, Cincinnati | 2020-01-13 |
| Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary Exacerbations (NCT04354038) | National Jewish Health | 2020-01-07 |
| PEP and OPEP Devices in Cystic Fibrosis (NCT05801952) | National Institute for Tuberculosis and Lung Diseases, Poland | 2020-01-01 |
| Comparison of the Efficacy of Comprehensive Respiratory Physiotherapy in Children With Cystic Fibrosis and Non-Cystic Fibrosis Bronchiectasis (NCT04170114) | Bezmialem Vakif University | 2020-01-01 |
| Hypoglycemia and Glucagon Response in CF (NCT05700604) | Marmara University | 2020-01-01 |
| Respiratory Function, Exercise Capacity and Peripheral Muscle Strength Among Patients With CF, PCD and Healthy Children (NCT04161313) | Bezmialem Vakif University | 2019-12-20 |
| CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis (NCT04206436) | Indiana University | 2019-12-18 |
| Validation of Respiratory Epithelial Functional Assessment to Predict Clinical Efficacy of Orkambi®. (NCT03894657) | Assistance Publique - Hôpitaux de Paris | 2019-12-18 |
| A Phase 2 Study of ABBV-3067 Alone and in Combination With ABBV-2222 (NCT03969888) | AbbVie | 2019-12-11 |
| Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy (NCT04058366) | Vertex Pharmaceuticals Incorporated | 2019-12-05 |
| Measuring and Improving Coproduction Using coopeRATE (NCT04060329) | Dartmouth-Hitchcock Medical Center | 2019-12-02 |
| Effects of SIMEOX on Airway Clearance in Cystic Fibrosis (NCT04187924) | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2019-11-27 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele (NCT04135495) | Eloxx Pharmaceuticals, Inc. | 2019-11-25 |
| A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD in Cystic Fibrosis Patients With at Least 1 G542X Allele (NCT04126473) | Eloxx Pharmaceuticals, Inc. | 2019-11-05 |
| Pain in Patients With Cystic Fibrosis in Rouen University Hospital (NCT04561973) | University Hospital, Rouen | 2019-11-04 |
| Cystic Fibrosis Adherence Study (NCT04217889) | Hospices Civils de Lyon | 2019-11-01 |
| Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions (NCT03938324) | Duke University | 2019-10-29 |
| Open-label, Dose-escalation Study to Evaluate the Pharmacokinetics of Inhaled Teicoplanin in Cystic Fibrosis Patients (NCT04176328) | Neupharma Srl | 2019-10-25 |
| A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Participants With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis (NCT03924947) | AbbVie | 2019-10-23 |
| A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (NCT04038047) | Nicole Hamblett | 2019-10-22 |
| A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del (NCT04105972) | Vertex Pharmaceuticals Incorporated | 2019-10-03 |
| Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis (NCT04010253) | Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche | 2019-09-30 |
| Parenting Concerns in Patients With Cystic Fibrosis (MucoPar) (NCT04133246) | Assistance Publique - Hôpitaux de Paris | 2019-09-25 |
| A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 (NCT04059094) | Boehringer Ingelheim | 2019-09-16 |
| A Comparison of Clinical Parameters in With and Without Abnormal Glucose Tolerance. (NCT04503408) | Hacettepe University | 2019-09-13 |
| STeP IT UP CF: STimulating ImProved Health And Well-being In CysTic Fibrosis (NCT04018495) | Medical College of Wisconsin | 2019-09-10 |
| Thoracic Mobility in Cystic Fibrosis Care (NCT04696198) | Göteborg University | 2019-09-09 |
| Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation (NCT04058548) | Boston Children's Hospital | 2019-09-05 |
| Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease. (NCT04038710) | National Jewish Health | 2019-09-05 |
| Trikafta in Cystic Fibrosis Patients (NCT03506061) | Emory University | 2019-09-04 |
| Gut Imaging for Function & Transit in Cystic Fibrosis Study 2 (NCT04006873) | Nottingham University Hospitals NHS Trust | 2019-09-03 |
| A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes) (NCT04058353) | Vertex Pharmaceuticals Incorporated | 2019-08-28 |
| A Study Evaluating the Long-term Safety of VX-445 Combination Therapy (NCT04043806) | Vertex Pharmaceuticals Incorporated | 2019-08-09 |
| Safety, Tolerability and Efficacy of S-1226 in Cystic Fibrosis and Non CF Bronchiectasis (NCT03903913) | SolAeroMed Inc. | 2019-08-08 |
| Inspiratory Muscle Training in Individuals With Cystic Fibrosis (NCT03737630) | Universidade Federal do Rio Grande do Norte | 2019-08-05 |
| Personalized Theratyping Trial (NCT03587961) | George Solomon | 2019-08-01 |
| Taste Receptors Regulation in CF Patients (NCT04058340) | Medical University of Lodz | 2019-07-30 |
| Role of Body Fat Distribution in Metabolic and Pulmonary Decline in Cystic Fibrosis (ORBIT-CF) (NCT04002882) | Emory University | 2019-07-08 |
| Anti-IL5 and Other Biotherapies in Cystic Fibrosis (NCT04256772) | University Hospital, Montpellier | 2019-07-01 |
| Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic Fibrosis (NCT04024423) | National Jewish Health | 2019-07-01 |